Weight-loss peptides are everywhere right now — but which ones actually have evidence behind them, and how do they work? Here's a clear, sourced answer.
Yes — certain peptides can support weight loss, and the evidence for the GLP-1 class is strong. Peptides like semaglutide, tirzepatide and retatrutide reduce appetite by mimicking gut hormones; in clinical trials they produced average weight loss of roughly 15% to 24% of body weight. Other peptides are researched for fat metabolism, but the GLP-1 group has by far the most robust data.
Last updated: July 2026 · For research use only · Not medical advice
A handful of peptides are studied for body composition. The GLP-1 receptor agonists have by far the strongest clinical evidence:
| Peptide | Class | Avg. trial weight loss | At Novapep |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% / 68 wks | from €75 → |
| Tirzepatide | GIP / GLP-1 | ~20.9% / 72 wks | from €75 → |
| Retatrutide | GIP / GLP-1 / glucagon | ~24.2% / 48 wks | from €98 → |
Figures come from separate trials — see the full Retatrutide vs Semaglutide vs Tirzepatide comparison for the detail and sources.
The GLP-1 class works mainly by reducing appetite. These peptides mimic the gut hormone GLP-1, slowing how fast the stomach empties and signalling fullness to the brain — so you eat less without the constant hunger that derails most diets.
That's also the limitation: they curb intake, they don't replace the fundamentals. Protein intake, resistance training and sleep still determine how much of the weight you lose is fat rather than muscle.
Trial averages hide a wide range — some people lose far more than the headline figure, others much less. Results build over months, not weeks, and usually require gradual dose increases (titration) to manage side effects.
The most common side effects are gastrointestinal — nausea and reduced appetite — usually strongest when the dose goes up. These are potent compounds supplied for research use only; a protocol built around your bloodwork and goals is the sensible way to approach them.
Browse the GLP-1 range, or read the full three-way comparison to see which fits your goals.
The GLP-1 peptides have strong clinical evidence — semaglutide, tirzepatide and retatrutide produced roughly 15%, 21% and 24% average weight loss in their trials. Other peptides marketed for fat loss have much weaker data.
In trial data, retatrutide showed the largest average weight loss, followed by tirzepatide then semaglutide — but retatrutide is still investigational. See our full comparison for the trade-offs between evidence, magnitude and safety.
Appetite usually drops within the first few weeks, but meaningful weight loss builds over months as the dose is titrated up. Trial results are measured at 48 to 72 weeks.
The main side effects in trials were gastrointestinal — nausea, diarrhoea, constipation — usually worst during dose increases. This is educational, not medical advice; consult a qualified clinician and use only lab-tested products.
Studies show some weight is typically regained after stopping GLP-1 compounds, which is why they are studied as long-term rather than short-term interventions. Sustained lifestyle changes help preserve results.
This page is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Some peptides discussed may be prescription-only or investigational in their approved contexts. All products supplied by Novapep are lab-tested and intended for research use only, not for human or veterinary consumption. Always consult a qualified healthcare professional before considering any compound.
Share your medical exams and we'll map the right peptide to your body and goals.